Literature DB >> 8016893

Receptors for ADP on human blood platelets.

S M Hourani1, D A Hall.   

Abstract

It is well established that ADP causes aggregation of human blood platelets, and indeed it was the first aggregating agent to be studied, but the ways in which platelets respond to ADP are still relatively obscure. Although it is apparent that increases in intracellular Ca2+ concentrations are of major importance in activating platelets, it is not clearly understood how ADP causes these increases and what other signal transduction mechanisms it uses. It is not even clear whether ADP causes its effects by interacting with only one receptor, or whether multiple receptors for ADP exist on platelets. In this review, Susanna Hourani and David Hall examine some of the conflicting evidence in this field, and draw some tentative conclusions about the number and nature of receptors for ADP on human platelets.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016893     DOI: 10.1016/0165-6147(94)90045-0

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  18 in total

1.  Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.

Authors:  H S Park; S M Hourani
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Distinct Ca(2+) signalling mechanisms induced by ATP and sphingosylphosphorylcholine in porcine aortic smooth muscle cells.

Authors:  T Y Chin; S H Chueh
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 3.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

4.  Activity of adenosine diphosphates and triphosphates on a P2Y(T) -type receptor in brain capillary endothelial cells.

Authors:  J Simon; P Vigne; K M Eklund; A D Michel; A M Carruthers; P P Humphrey; C Frelin; E A Barnard
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

Authors:  A Sugidachi; F Asai; K Yoneda; R Iwamura; T Ogawa; K Otsuguro; H Koike
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

6.  The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.

Authors:  A Sugidachi; F Asai; T Ogawa; T Inoue; H Koike
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  P2Y(2) receptor-mediated proliferation of C(6) glioma cells via activation of Ras/Raf/MEK/MAPK pathway.

Authors:  M T Tu; S F Luo; C C Wang; C S Chien; C T Chiu; C C Lin; C M Yang
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

8.  ADP-induced rapid inward currents through Ca(2+)-permeable cation channels in mouse, rat and guinea-pig megakaryocytes: a patch-clamp study.

Authors:  K Kawa
Journal:  J Physiol       Date:  1996-09-01       Impact factor: 5.182

9.  RhoA downstream of G(q) and G(12/13) pathways regulates protease-activated receptor-mediated dense granule release in platelets.

Authors:  Jianguo Jin; Yingying Mao; Dafydd Thomas; Soochong Kim; James L Daniel; Satya P Kunapuli
Journal:  Biochem Pharmacol       Date:  2008-11-25       Impact factor: 5.858

Review 10.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.